Under the Microscope: Antisense Therapeutics (ASX: ANP), Mark Diamond, Chief Executive Officer by Morgans Financial Limited published on 2018-12-18T05:42:50Z The Morgans Healthcare team speaks with Mark Diamond, CEO from Antisense Therapeutics. Antisense is undertaking a Phase 2 trial in Duchenne Muscular Dystrophy with results expected to read out in 3QCY19. Genre Business
